OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. McDermott on Immunotherapy as a Standard of Care in RCC

December 28th 2017

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses immunotherapy as a standard of care for patients with renal cell carcinoma (RCC).

Dr. Reckamp on Molecular Testing in Lung Cancer

December 28th 2017

Karen Reckamp, MD, MS, medical oncologist, City of Hope, discusses the role of molecular testing for patients with lung cancer.

Dr. Hensley on Lynch Syndrome in Endometrial Cancer

December 28th 2017

Martee L. Hensley, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses Lynch syndrome for patients with endometrial cancer.

Dr. Agarwal on Androgen Receptor Inhibitors for Prostate Cancer

December 27th 2017

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses androgen receptor (AR) inhibitors for patients with prostate cancer.

Dr. Pal on the Mutational Burden in Bladder Cancer

December 27th 2017

Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at City of Hope, discusses the mutational burden for patients with bladder cancer.

Dr. Ledermann on Systemic Treatment for Rare Gynecologic Tumors

December 27th 2017

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses systemic treatment for patients with rare gynecologic tumors.

Dr. Graff on the Role of Checkpoint Inhibitors in Prostate Cancer

December 27th 2017

Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the role of checkpoint inhibitors and PARP inhibitors for patients with prostate cancer.

Dr. Heinzerling on Stage III Treatment of NSCLC

December 26th 2017

Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses the treatment of patients with stage III non-small cell lung cancer (NSCLC).

Dr. Voss on the Future of Clinical Trials for Kidney Cancer

December 26th 2017

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future of the clinical trial space for patients with kidney cancer.

Dr. Atkinson Discusses BRAF-Mutant Metastatic Melanoma

December 22nd 2017

Victoria Atkinson, MD, medical oncologist, Princess Alexandra Hospital, University of Queensland, discusses the treatment landscape for patients with BRAF-mutant metastatic melanoma.

Dr. Rogers Discusses Obinutuzumab, Ibrutinib, and Venetoclax Combination in CLL

December 22nd 2017

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the initial results of the phase II treatment-naïve cohort in a phase Ib/II study of obinutuzumab (Gazyva), ibrutinib (Imbruvica), and venetoclax (Vencelxta) in chronic lymphocytic leukemia (CLL).

Dr. Marshall Discusses Frontline Treatment for CRC

December 22nd 2017

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses frontline treatment options for patients with colorectal cancer (CRC).

Dr. Wang Discusses Acalabrutinib in MCL

December 22nd 2017

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses acalabrutinib (Calquence) in mantle cell lymphoma.

Dr. Cohen on Immunotherapy Combinations in Head and Neck Cancer

December 22nd 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy combinations in head and neck cancer.

Dr. McCloskey Discusses Targeting CD19 in B-Cell ALL

December 22nd 2017

James K. McCloskey II, MD, medical oncologist, Division of Leukemia and the Adult Blood and Marrow Stem Cell Transplantation Program, John Theurer Cancer Center, discusses targeting CD19 in patients with acute lymphocytic leukemia.

Dr. Taylor on the Current Treatment Landscape for Endometrial Cancer

December 21st 2017

Alexandra Taylor, MD, consultant, clinical oncology, The Royal Marsden Hospital, discusses the current treatment landscape of advanced endometrial cancer.

Dr. Sampath on Immunotherapy and Radiation Combinations in NSCLC

December 21st 2017

Sagus Sampath, MD, assistant professor, Department of Radiation Oncology, City of Hope, discusses combinations of immunotherapy and radiation for the treatment of patients with non-small cell lung cancer (NSCLC).

Dr. Usmani on the Gimema-MMY-3006 Study for Multiple Myeloma

December 21st 2017

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses the phase III Gimema-MMY-3006 study for patients with multiple myeloma.

Dr. Hamilton on FDA Approval of Adjuvant Pertuzumab Regimen in HER2+ Early Breast Cancer

December 21st 2017

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research Program, Sarah Cannon Research Institute, discusses the FDA approval of pertuzumab (Perjeta) for use in combination with trastuzumab (Herceptin) and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer.

Dr. Apolo on Toxicity Challenges With Checkpoint Inhibitors in Bladder Cancer

December 21st 2017

Andrea B. Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses challenges with managing toxicities of checkpoint inhibitors for patients with bladder cancer.